Hematopoietic growth factors and chemoprotectants: should we move toward a two-step process for phase I clinical trials in oncology?
Merrouche
Y
Y
Medical Oncology Department, Centre Léon Bérard, Lyon, France.
Catimel
G
G
Clavel
M
M
D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000009:adverse effects*; D017321:Clinical Trials, Phase I as Topic; D006331:Heart Diseases / Q000139:chemically induced / Q000517:prevention & control; D016298:Hematopoietic Cell Growth Factors / Q000627:therapeutic use*; D006801:Humans; D007674:Kidney Diseases / Q000139:chemically induced / Q000517:prevention & control; D009369:Neoplasms / Q000188:drug therapy*; D009503:Neutropenia / Q000139:chemically induced / Q000517:prevention & control; D011929:Razoxane / Q000627:therapeutic use
D000970:Antineoplastic Agents; D016298:Hematopoietic Cell Growth Factors; D011929:Razoxane